Article Text

Download PDFPDF

Original research article
Haemodynamic outcomes following aortic valve-in-valve procedure
  1. Anne-Sophie Zenses1,2,
  2. Abdellaziz Dahou1,
  3. Erwan Salaun1,
  4. Marie-Annick Clavel1,
  5. Josep Rodés-Cabau1,
  6. Géraldine Ong1,
  7. Ezéquiel Guzzetti1,
  8. Mélanie Côté1,
  9. Robert De Larochellière1,
  10. Jean-Michel Paradis1,
  11. Daniel Doyle1,
  12. Siamak Mohammadi1,
  13. Éric Dumont1,
  14. Chekrallah Chamandi1,
  15. Tania Rodriguez-Gabella1,
  16. Régis Rieu2 and
  17. Philippe Pibarot1
  1. 1 Quebec Heart and Lung Institute, Laval University, Quebec, Canada
  2. 2 IFSTTAR, LBA UMR_T24, Aix-Marseille Univ, Marseille, France
  1. Correspondence to Dr Philippe Pibarot; philippe.pibarot{at}med.ulaval.ca

Abstract

Background and objectives Transcatheter aortic valve-in-valve implantation (ViV) has emerged as a valuable technique to treat failed surgical bioprostheses (BPs) in patients with high risk for redo surgical aortic valve replacement (SAVR). Small BP size (≤21 mm), stenotic pattern of degeneration and pre-existing prosthesis–patient mismatch (PPM) have been associated with worse clinical outcomes after ViV. However, no study has evaluated the actual haemodynamic benefit associated with ViV. This study aims to compare haemodynamic status observed at post-ViV, pre-ViV and early after initial SAVR and to determine the factors associated with worse haemodynamic outcomes following ViV, including the rates of high residual gradient and ‘haemodynamic futility’.

Methods Early post-SAVR, pre-ViV and post-ViV echocardiographic data of 79 consecutive patients who underwent aortic ViV at our institution were retrospectively analysed. The primary study endpoint was suboptimal valve haemodynamics (SVH) following ViV defined by the Valve Academic Research Consortium 2 as the presence of high residual aortic mean gradient (≥20 mm Hg) and/or at least moderate aortic regurgitation (AR). Haemodynamic futility of ViV was defined as <10 mm Hg decrease in mean aortic gradient and no improvement in AR compared with pre-ViV.

Results SVH was found in 61% of patients (57% high residual gradient, 4% moderate AR) after ViV versus 24% early after SAVR. Pre-existing PPM and BP mode of failure by stenosis were independently associated with the primary endpoint (OR: 2.87; 95% CI 1.08 to 7.65; p=0.035 and OR: 3.02; 95% CI 1.08 to 8.42; p=0.035, respectively) and with the presence of high residual gradient (OR: 4.38; 95% CI 1.55 to 12.37; p=0.005 and OR: 5.37; 95% CI 1.77 to 16.30; p=0.003, respectively) following ViV. Criteria of ViV haemodynamic futility were met in 7.6% overall and more frequently in patients with pre-existing PPM and stenotic BP (18.5%) compared with other patients (2.0%). ViV restored haemodynamic function to early post-SAVR level in only 34% of patients.

Conclusion Although ViV was associated with significant haemodynamic improvement compared with pre-ViV in >90% of patients, more than half harboured SVH outcome. Furthermore, only one-third of patients had a restoration of valve haemodynamic function to the early post-SAVR level. Pre-existing PPM and stenosis pattern of BP degeneration were the main factors associated with SVH and haemodynamic futility following ViV. These findings provide strong support for the prevention of PPM at the time of initial SAVR and careful preprocedural patient screening.

  • transcatheter aortic valve-in-valve
  • bioprosthesis dysfunction
  • hemodynamics
  • hemodynamic futility
  • prosthesis-patient mismatch

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors The study was planned and conducted by A-SZ and PP. AD, ES, JR-C, MC, RDL, J-MP, DD, SM, ER, CC and TR-G were involved in clinical and/or echocardiographic data acquisition. A-SZ, AD, ES, M-AC and PP performed and/or supervised data management and statistical analyses. A-SZ, AD, ES, M-AC, GO, EG, RR and PP contributed to the interpretation of the data. The manuscript was drafted by A-SZ. ES, M-AC, GO, EG and PP made critical revisions. All authors read and approved the final manuscript.

  • Funding This study was funded by a Foundation Scheme Grant (#FDN-143225) from Canadian Institutes of Health Research (Ottawa, Ontario, Canada). PP holds the Canada Research Chair in Valvular Heart Disease. JR-C holds the Research Chair on the Development of Interventional Therapies for Structural Heart Diseases – Family Jacques Larivière Foundation.

  • Competing interests PP and JR-C report research grant from Edwards Lifesciences and Medtronic.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.